Tübingen, Germany – Acousia Therapeutics GmbH, a clinical-stage biotechnology company, has announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. The study is focused on developing treatments for acute and chronic inner ear hearing loss. The company’s proprietary drug candidate, ACOU085 (INN: Bimokalner), has shown promising results in multiple preclinical hearing...

Source